Serojec

Drugs for Treating Premature Ejaculation

Health Tech & Life Sciences
Active
Pre-Funding Tel Aviv-Yafo, Israel Founded 2019
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2019
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Serojec develops drugs to treat premature ejaculation, by combining various drugs on the market. One drug is from the tricyclic family of antidepressants, used in low dosage, which then reaches only the spinal column, not the brain. The second drug is an alkaloid that relaxes the blood vessels. The combination enables each drug to neutralize the other's side effects. The alkaloid is a known drug for the treatment of premature ejaculation. The combinations of both drugs are patented. The company has completed a Phase I trial to verify that the project is safe. A secondary purpose was to show signs of effectiveness. The trial showed that the duration of erection was extended several times over, even though all of the volunteers in the trial were functioning normally. The trial was conducted in cooperation with the University of Vienna.

Q&A

What is Serojec's primary focus?
Serojec develops drugs for treating premature ejaculation by combining existing medications.
What is the composition of Serojec's drug combination?
Serojec's drug combines a low-dosage tricyclic antidepressant, which targets the spinal column, with an alkaloid that relaxes blood vessels. This combination is designed to neutralize each drug's side effects.
Has Serojec patented its drug combination?
Yes, the combinations of both drugs developed by Serojec are patented.
What is the current development stage of Serojec's product?
Serojec has completed a Phase I clinical trial for its drug.
What were the results of Serojec's Phase I trial?
The Phase I trial verified the project's safety and showed signs of effectiveness, including an extended duration of erection, even in volunteers who were functioning normally.
With which institution did Serojec cooperate for its Phase I trial?
Serojec conducted its Phase I trial in cooperation with the University of Vienna.
When was Serojec founded?
Serojec was founded in January 2019.
Who is the founder of Serojec?
Dr. Daniel Drai is the founder of Serojec.

Team · 1

Founder · Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

pharmaceuticalstreatmentsurologydrug-developmentpharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2019-1
Employees (exact)6